WitrynaOur pipeline includes Tissue-Specific Therapeutics and Tissue-Specific Biologics for soft tissue sarcoma, colorectal cancer, and inflammatory bowel disease. We believe our … WitrynaArrowhead Pharmaceuticals Inc -74.80% 137.4% 237.5% 410.7% ... Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics …
Kevin T. Skol - Biografia
Witryna12 kwi 2024 · The main competitors of Immix Biopharma include Tempest Therapeutics (TPST), Equillium (EQ), TFF Pharmaceuticals (TFFP), AgeX Therapeutics (AGE), … WitrynaIMMX Stock Price - Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and schwab windows 10 app
IMMIX BIOPHARMA, INC. : Shareholders Board Members …
WitrynaImmix Biopharma, Inc - Tissue-Specific Therapeutics (TSTx) Targeting Oncology & Immuno-Dysregulated Diseases Immix Biopharma, Inc - Tissue-Specific Therapeutics (TSTx) Targeting … Our pipeline includes Tissue-Specific Therapeutics and Tissue-Specific … WitrynaImmix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology … Witryna20 gru 2024 · -- Immix Biopharma said late Monday it closed its initial public offering of 4.2 million common shares at $5 each, raising $21 million in gross proceeds. Underwriters hold an overallotment option... April 5, 2024 schwab winter park fl